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ABSTRACT
Identifying which mutation(s) within a given
genotype is responsible for an observable
phenotype is important in many aspects of
molecular biology. Here, we present SigniSite, an
online application for subgroup-free residue-level
genotype–phenotype correlation. In contrast to
similar methods, SigniSite does not require any
pre-definition of subgroups or binary classification.
Input is a set of protein sequences where each
sequence has an associated real number, quantify-
ing a given phenotype. SigniSite will then identify
which amino acid residues are significantly
associated with the data set phenotype. As output,
SigniSite displays a sequence logo, depicting the
strength of the phenotype association of each
residue and a heat-map identifying ‘hot’ or ‘cold’
regions. SigniSite was benchmarked against
SPEER, a state-of-the-art method for the prediction
of specificity determining positions (SDP) using a
set of human immunodeficiency virus protease-in-
hibitor genotype–phenotype data and correspond-
ing resistance mutation scores from the Stanford
University HIV Drug Resistance Database, and a
data set of protein families with experimentally
annotated SDPs. For both data sets, SigniSite was
found to outperform SPEER. SigniSite is available at:
http://www.cbs.dtu.dk/services/SigniSite/.
INTRODUCTION
Whether conducting research in vaccine design or trying
to elucidate the intimate details of a given receptor::ligand
interaction, genotype–phenotype correlation is a powerful
tool to enhance the understanding of the minute subtleties,
often characterizing research within the ﬁeld of molecular
biology.
The traditional approach for wet-laboratory analysis of
genotype–phenotype correlations involves site-directed
mutagenesis and subsequent quantiﬁcation of mutation-
impact on the phenotype, e.g. binding-afﬁnity or catalytic
efﬁciency. This approach of mutating all amino acid
residues in a given protein is a time consuming and
tedious task. Random mutagenesis has the advantage of
introducing a large number of random mutations
throughout the protein. One example of application of
random mutagenesis is to increase the signal from near-
infrared ﬂuorescent proteins (1). In such a panel of
sequenced variants with multiple mutations, it is a
complex task to systematically pinpoint the exact amino
acid residue(s), i.e. the genotype, associated with a given
phenotype (e.g. ﬂuorescence). Another area of application
is genotype–phenotype association studies in proteins,
which show inherent natural variability, as is the case
for instance for proteins involved in the pathogenesis of
malaria (2).
Here, we present SigniSite, an online application for
subgroup-free residue-level genotype–phenotype correl-
ation in protein multiple sequence alignments (MSAs). A
number of methods have been developed for the identiﬁ-
cation of functional sites in protein sequences (3–10), most
requiring a deﬁnition of functional subgroups before
analysis. However, if the phenotype associated with the
sequences is not categorical (e.g. substrate-speciﬁcity)
but continuous (e.g. catalytic efﬁciency), a pre-division
of sequences subgroups is none trivial. In contrast,
SigniSite does not require any subgroup division or
binary classiﬁcation. Instead, SigniSite directly analyses
the raw sequences and associated continuous values. The
main novelty of SigniSite is that unlike conventional
methods for the prediction of speciﬁcity determining
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positions (SDP), it not only predicts the positions in the
MSA determining a given protein function but also makes
a statistical evaluation of which types of amino acid
residue substitutions (genotype) are associated with the
observable phenotype at the SDP.
The web server implementation of the SigniSite method
described here is an automatized online application with
an easy-to-interpret graphical output. The application is
easy to use for the non-expert end-user and aims at aiding
researchers in the analysis of sequence data, where the
phenotype is quantiﬁed by a real number. A list of abbre-
viations is available in the Supplementary Data.
THE WEB SERVER
User interface
The SigniSite server is intended to provide the non-expert
user with a simple interface. At default settings, an amino
acid residue is considered signiﬁcantly associated with the
MSA phenotype, if the P-value for the speciﬁc residue is
smaller than or equal to  ¼ 0:05 after Bonferroni Single-
Step Correction for Multiple Testing (CMT) (11). On the
submission page, sequences can be submitted to the server
either as paste-in or via the ﬁle upload ﬁeld. On submis-
sion, SigniSite will check whether the submitted sequences
are aligned. If not, an MSA will be created using MAFFT
(12). SigniSite will exclude any characters other than the
one-letter representation of the 20 standard proteogenic
amino acids from the analysis.
Input
As input SigniSite takes an MSA in FASTA-format
(minimum two sequences). Each sequence must have an
associated real number, stated white-space-separated as
the last element in its FASTA header. At least two differ-
ent values must exist in the MSA. The MSA is assumed
pre-sorted, if the end-placed value is absent. A section
with options for customizing the analysis is available.
The following parameters are user-adjustable: (i) the
level of signiﬁcance ‘a’, 0    1 (default is 0.05). (ii)
The method for CMT: ‘Bonferroni Single-Step’ (default),
‘Holm Step-Down’ (11) or ‘no correction’. (iii) The sorting
of the sequences: ‘Decreasing’, highest sequence-
associated value is considered the strongest, e.g. ﬂuores-
cent protein signals, and vice versa for ‘Increasing’, e.g.
binding afﬁnity. Furthermore, the user can choose a ref-
erence sequence to assign sequence-speciﬁc positional
output numbering. This is useful, when the MSA
contains insertions. Finally, the user can modify the logo
output by choosing to include either ‘Signiﬁcant positions’
(default, displays all residues at positions where at least
one amino acid residue has been identiﬁed as signiﬁcantly
associated with the data set phenotype), ‘Signiﬁcant
Residues’ (as for signiﬁcant positions, but only including
signiﬁcant residues) or ‘Full Logo’ (all residues at all pos-
itions). At the results page, a button below the generated
logo allows the user to fully customize the logo using
Seq2Logo (13).
Output
The SigniSite output is intended to provide the end-user
with an easily interpretable graphical representation of the
statistical evaluations performed by SigniSite. An example
of a sequence logo (13) generated by SigniSite is shown in
Figure 1. The logo gives an overview of residue associ-
ations. See Figure 1 legend for further details. SigniSite
will also generate a heatmap (Figure 2). The heatmap is
intended to give a graphic overview of ‘hot’ and ‘cold’
regions in the MSA, with respect to the data set pheno-
type. See Figure 2 legend for details.
RESULTS
As an initial performance evaluation, we chose to analyse
18 human immunodeﬁciency virus type 1 (HIV-1) MSAs
compiled from the Stanford University HIV Drug
Resistance Database (15,16) (HIVdb) using Spearman’s
rank correlation (SCC) to correlate the obtained
SigniSite Z-scores (zp,a for each residue a at each
position p) with the table of resistance mutation scores
(RMS) also available from the HIVdb (see ‘Materials
and Methods’ section), i.e. SCC zp,a  RMS
 
. Results
are given in Table 1.
As the SCC evaluation is threshold dependent, a
threshold-independent performance evaluation was
added using the area under the receiver operator
Figure 1. Sequence logo. Example of sequence logo (13) output from
SigniSite from the analysis of the ATV Antivirogram multiple
sequence alignment (MSA), truncated to p1 – p35 for the purpose of
illustration (see ‘Materials and Methods’ section). The analysis was
performed with default settings. On the x-axis are the MSA positions
p and on the y-axis the Z-scores for each amino acid residue a (zp,a).
The height of each letter representing the residues is proportional to
zp,a, i.e. the strength of the statistical association between the residue
and the data set-phenotype. Residues above the Z=0 line have a
zp,a > 0, i.e. enhances the phenotype, whereas residues below the
Z=0 line have a zp,a < 0, i.e. inhibits the phenotype, e.g. the
presence of a certain residue with favourable chemical properties may
enhance binding (zp,a > 0), whereas a residue with unfavourable
properties may inhibit binding (zp,a < 0). Colour-coding: acidic [DE]:
red, basic [HKR]: blue, hydrophobic [ACFILMPVW]: black and
neutral [GNQSTY]: green (14).
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characteristics curve (AUC) measure, resulting in
AUC zp,a  RMSbin
  ¼ 0:791 0:010. Certain mutations
not included in the RMS were repeatedly identiﬁed by
SigniSite. As the majority of these mutations were
found in the binary resistance annotations from the
international antiviral society-USA (IAS) (17), we
enriched the RMSbin with the IAS and re-calculated
the AUC, obtaining a signiﬁcant performance increase
of AUC zp,a  ðRMS+IASÞmut
 ¼ 0:822 0.011(P=
5.16  104), two-tailed paired t-test).
Furthermore, we evaluated the performance of
SigniSite using performance measures: Matthew’s correl-
ation coefﬁcient (MCC), sensitivity (SENS) and speciﬁcity
(SPEC) against (RMS+IAS)mut. See Table 1 for results.
Having obtained good results for both the threshold-
dependent and -independent performance evaluations,
we turned to benchmark SigniSite against similar
existing methods. In a 2009 benchmark study (18),
SPEER (5,19) was identiﬁed as the state-of-the-art
method for prediction of speciﬁcity deﬁnition positions
(SDP). We, therefore, here compared the performances
of SigniSite and SPEER on each of their original bench-
marks data sets (see ‘Materials and Methods’ section)
against (RMS+IAS)pos. The results are shown in
Figure 3. The results show that SigniSite outperforms
SPEER on both data sets. The difference in predictive
performance was, however, only found to be statistically
signiﬁcant for the HIVdb data set.
DISCUSSION
SigniSite aims at providing a simple-to-use method
for subgroup-free residue-level genotype–phenotype cor-
relation in protein MSAs. SigniSite, thus, addresses a
long-existing challenge in molecular biology; genotype-
phenotype mapping. Genotype–phenotype mapping has
a wide range of purposes in molecular biology, e.g. struc-
tural regions responsible for immunity (2), identifying
protein-variants responsible for the severity of a disease
(20) or coupling receptor polymorphisms to surface
expression (21) etc.
Site-directed mutagenesis in proteins and subsequent
quantiﬁcation of mutation-impact on a given phenotype
is a time consuming and tedious task. High-throughput
methods such as e.g. random mutagenesis (1) have, there-
fore, been developed. However, the challenge of analysing
the increasingly larger volumes of data being generated
only becomes greater. Additionally, large genotype–
phenotype data sets (GPDs) can be compiled from
publicly available databases, such as the HIVdb (15,16).
SigniSite addresses this exact challenge.
Figure 2. SigniSite heatmap from the analysis of the
ATV Antivirogram multiple sequence alignment (MSA), truncated
to p1 – p35 for the purpose of illustration (see ‘Materials and
Methods’ section). The analysis was performed with default settings.
On the x-axis are the 20 proteogenic amino acids a and on the y-axis
the positions p in the analysed MSA. The colour coding of the ﬁelds is
such that ﬁelds reﬂecting zp,a  5 are blue, whereas zp,a  5 results in
a red ﬁeld. For 5 < zp,a < 5, nuances in between are used. If a residue
has a zp,a of 0, the cell is coloured grey. Absent residues are coloured
black. If only one grey cell is present at a given position, this implies
that the position is fully conserved, harbouring only this residue. If
more grey cells are present, their associated P-values have become
P ¼ 1) zp,a ¼ 0 after correction for multiple testing.
Table 1. Benchmark results
Measure jzj  0 jzj  1:96 jzj  1:96CMT
SCCa 0:451 0:015 0:506 0:016 0:542 0:020
MCCb 0:492 0:028 0:387 0:027 0:297 0:040
SENSb 0:915 0:015 0:598 0:056 0:386 0:055
SPECb 0:579 0:016 0:774 0:031 0:882 0:022
aCalculated against the RMS.
bCalculated against the (RMS+IAS)mut.
Measures are means±SE. CMT: corrected for multiple testing, SCC:
Spearman’s rank correlation, MCC: Matthews Correlation Coefﬁcient,
SENS: sensitivity, SPEC: speciﬁcity.
Figure 3. Measures are mean (AUC)±SE. Columns are: HIV
[SPEER/SIGNI], SPEER and SigniSite’s predictions on the HIVdb
data set. SDP [SPEER/SIGNI] SPEER and SigniSite’s predictions on
the SDP data set. P-values quantifying the signiﬁcance of the difference
in performance were obtained using a two-tailed paired t-test.
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SigniSite was benchmarked on publicly available GPDs
and RMS from the Stanford University HIV Drug
Resistance Database (HIVdb) (15,16). We observed that
for each of the 18 different benchmark data sets, SigniSite
consistently identiﬁed certain residues, not annotated in
the RMS table, as signiﬁcantly associated with anti-viral
drug resistance. We compared these identiﬁcations with
binary resistance annotations from the International
Antiviral Society-USA (IAS) (17) and found that the
majority were indeed annotated as resistance impacting.
This observation suggests that the RMS data are not
exhaustive, and that the obtained correlation should
rather be regarded as a lower bound of the true predictive
performance.
As the SDP method SPEER (5,19) was found to be
the state-of-the-art method in a 2009 benchmark study
(18), we chose to compare SigniSite to SPEER. We
observed that SigniSite signiﬁcantly outperformed
SPEER on the HIVdb data set (P ¼ 3:77  106) and
for the SDP data set (as deﬁned in the SPEER paper),
SigniSite likewise outperformed SPEER, approaching a
signiﬁcant difference (P ¼ 0:0678). Furthermore,
SigniSite was much faster, taking only a few minutes to
analyse the largest of the MSA (nseqs ¼ 1,374). SPEER
on the other hand requires to be compiled in a slower
version, when nseqs > 200, taking 2 h to complete the
analysis.
In conclusion, SigniSite provides two important novel
features: (i) SigniSite does not require any manual anno-
tation of the data before analysis, e.g. binder/non-binder
classiﬁcation, SigniSite requires only sequences and
associated values. (ii) Unlike conventional SDP prediction
methods like SPEER, SigniSite will not only identify pos-
itions impacting the phenotype but also pinpoint the exact
amino acid residue substitution(s) responsible for the
impact detected at the identiﬁed position. To the best of
our knowledge, this level of resolution has so far not been
available.
MATERIALS AND METHODS
Benchmark data sets
Summary, see Supplementary Data for details.
HIVdb resistance mutation scores
The table of RMS was downloaded from the
HIVdb (15,16), available at http://hivdb.stanford.
edu/DR/cgi-bin/rules_scores_hivdb.cgi?class=PI. The
table of RMS contains information about positions
known to harbour mutations (n=688) compared with
wild-type (WT) and their impact on resistance towards
eight different protease inhibitors (PIs). Positive
scores range is [3,60] (n=296) and indicates that the
mutation increases the resistance towards a given PI.
Negative score range is ½5,  10 (n=15) and indicates
a decreased resistance. Scores of 0 (n=377) indicate lack
of resistance impact. At each position annotated in the
table of RMS, the consensus residue was assigned an
RMS of 0.
IAS resistance annotations
Protease mutations known to impact PI resistance were
retrieved from the table ‘mutations in the protease gene
associated with resistance to protease inhibitors’, in the
International Antiviral Society USA (IAS)’s Update of
the Drug Resistance Mutations in HIV-1: March 2013
(17). Also here, the consensus residue at annotated resist-
ance positions was assigned an IAS score of 0.
Table transformations
The following table transformations were performed:
RMS! RMSbin, such that RMS > 0) RMSbin ¼ 1,
otherwise RMSbin ¼ 0: RMSbin+IAS! ðRMS+IASÞmut,
such that RMSbin > 0 or IAS > 0) ðRMS+IASÞmut ¼ 1,
otherwise ðRMS+IASÞmut ¼ 0: ðRMS+ IASÞpos, such that
for each position in (RMS+IAS)mut the resulting
ðRMS+IASÞpos ¼ 1 if at least one ðRMS+IASÞmut > 0,
otherwise ðRMS+IASÞpos ¼ 0. In all tables, any score
stable > 0 is considered an actual positive and any score
stable  0 is considered an actual negative (Table 2).
MSAs from the HIVdb protease GPDs
GPDs were downloaded from the Stanford University
HIV Drug Resistance Database (HIVdb) (15,16) Version
5.0, March, 2012, available at http://HIVdb.stanford.edu/
cgi-bin/GenoPhenoDS.cgi. MSAs were compiled from the
GPDs. Each MSA contains the sequences of a set of
HIV-1 protease variants with measured fold change in
resistance (compared with WT) towards the same PI,
measured using the same assay. Only PIs present in both
the table of RMS and the GPDs were used limiting the
analysis to 6 PIs: ATV, IDV, LPV, NFV, SQV and TPV
each of which was assayed using the three assays:
‘Antivirogram’ (VircoTM), ‘PhenoSense’ (ViroLogicTM)
and ‘All Others’. A total of 12 714 sequences were con-
structed and compiled into 18 MSAs. The length of each
of the protease variants is 99 amino acid residues.
The SPEER program and SDP benchmark data
SPEER, MSAs and corresponding experimentally
annotated speciﬁcity determining sites were downloaded
from the SPEER repository available at: ftp://ftp.ncbi.nih.
gov/pub/SPEER/ (5,19). We downloaded the latest
curated version of the data as described by Chakrabarti
and Panchenko (18).
The SigniSite method
The method takes a set of (protein) sequences as input.
If the sequences are not aligned, Signisite will use
MAFFT (12) to make an MSA from the input
sequences. Subsequently, the sequences are ranked with
respect to a real number associated with each sequence,
e.g. the replicative capacity or catalytic efﬁciency. For
each amino acid at each position in the MSA, a non-
parametric test is performed to test whether the
observed ranks deviate signiﬁcantly from the expected
ranks. CMT of the resulting P-values may be performed
using Bonferroni single-step or Holm step-down proced-
ures. The resulting Z-scores per residue are visualized in a
logo plot and a heatmap.
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Brief description of the method underlying SigniSite
(see Supplementary Data for details). Initially each
sequence is assigned a rank by sorting the sequence
associated values (either ascending or descending depend-
ing on type of value) and then assigning a rank of ‘1’ to the
ﬁrst sequence after sorting, ‘2’ to the second and so forth.
Each amino acid residue a observed at position p (resp,a) in
the MSA is then assigned the rank of the sequence to
which it belongs. This way each resp,a is associated with
a speciﬁc rank. At each position in the MSA, the mean
ranks of each residue type are then calculated and placed
in a rank matrix, where each row corresponds to a
position in the MSA and each column to one of the 20
standard proteogenic amino acids, sorted according to A,
R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V
(SigniSite will exclude any characters but these 20).
Subsequently, SigniSite evaluates for each position and
residue type the difference between the mean of the
observed and expected ranks. The mean of the expected
ranks is the mean of the ranks we would observe if the
residue type resp,a was randomly distributed over the
column p in the MSA. This difference between observed
and expected ranks is quantiﬁed by a Z-score assigned to
each residue type at each position, yielding a Z-score-
matrix. If a given position is fully conserved, z=0 is
assigned to the conserved residue. If a given residue type
is absent at a given position, z ¼ 0NA0 is assigned.
The non-parametric statistics, on which SigniSite is
based, are similar to that of Wilcoxon test statistics (22),
where the obtained evaluation scores can be approximated
by the standard normal distribution, thus allowing
Z-score conversion to P-values by standard method. As
one test is performed per residue type, per position,
SigniSite will by default apply Bonferroni single-step
(11) CMT to adjust the reported P-values.
Benchmarking
For each of the 18 MSAs compiled from the HIVdb GPDs
(see ‘Materials and Methods’ section), a set of predictions
were made (Z-scores) estimating the strength of the asso-
ciation of each residue type a at each position p (zp,a) to
the phenotype of the MSA. The obtained set of zp,a’s was
then correlated with the RMS using Spearman’s rank cor-
relation (SCC) at three signiﬁcance thresholds: including
residues for which: (i) P  1, (ii) P  0:05 and (iii)
P  0:05 after CMT. The SCC was recorded for each of
the 18 MSAs, and the mean and standard error (SE) of the
means were calculated.
For evaluating threshold-independent performance, the
AUC measure was applied. The AUC was calculated
against two sets of targets: RMSbin and the enriched set
of targets (RMS+IAS)mut. The mean AUC and SE were
calculated for each set of targets.
Finally, the sensitivity, speciﬁcity and MCC were
calculated at the same thresholds as the SCC against the
enriched set of targets (RMS+IAS)mut. The sensitivity,
speciﬁcity and MCC were recorded for each of the 18
MSAs, and the means and SEs were calculated.
Comparing SigniSite and SPEER
To compare the performance of SigniSite with that of
existing methods, we turned to a 2009 benchmark study
by Chakrabarti and Panchenko (18) comparing the pre-
dictive performance of ﬁve SDP prediction methods, on a
set of protein families with experimentally annotated
SDPs. As SPEER (5,19) in this benchmark was found to
be the best performing method, we here limit our analysis
to comparing SigniSite and SPEER by applying both
methods to their respective GPDs.
SPEER outputs positional predictions, whereas
SigniSite assigns a Z-score for each residue type at each
position. To cast the SigniSite Z-scores into one score per
positions, the maximum of the absolute Z-scores was
chosen.
SigniSite assigns a prediction value to all positions re-
gardless of residue composition, whereas SPEER by
default will skip any fully conserved and positions with
>20% gaps. To get prediction values for all positions,
we assign a value of ‘100’ to positions not predicted by
SPEER (this value is lower than any score predicted
by SPEER).
SPEER requires each sequence in an MSA to be
subgroup-annotated before analysis. To accommodate
this requirement, each HIV MSA was split into two sub-
groups, by sorting the sequences in the MSA descending
on their associated real values and then splitting the se-
quences into subgroup ‘1’ or ‘2’ on the median of the
sorted values.
To perform the rank analysis SigniSite requires that
each sequence in the MSA has an associated real
number. Of the 20 SDP MSAs, 13 contain only subgroups
‘1’ and ‘2’. We chose to use these 13 MSAs for the bench-
mark, using ‘1’ or ‘2’ as ‘SigniSite real number values’.
This way the following two comparisons were made:
SigniSite versus SPEER on the HIV protease data set
and SigniSite versus SPEER in the SDP data set. The
AUC measure was used to quantify the performance of
each method on each benchmark data set.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary description of the SigniSite Method,
Table 2. Overview of target table notation
Notation Format Level Annotating
RMSa Real num. Residue Fold-change in PI resistance
IASb Binary Residue PI ass. resistance mutations
RMSbin
c Binary Residue PI ass. resistance mutations
(RMS+IAS)mut
d Binary Residue PI ass. resistance mutations
(RMS+IAS)pos
e Binary Position Positions ass. with PI
resistance
aIt is used when calculating SCC, bit is used to look up mutations not
annotated in 1, but repeatedly identiﬁed by SigniSite, cit is used when
calculating AUC, dit is used for the enriched AUC calculation and
when calculating the MCC, SENS and SPEC, eit is used as positional
targets, when comparing the predictive performances of SigniSite and
SPEER.
‘num.’, ‘ass.’, ‘PI’ abbreviates ‘numbers’, ‘association’ and ‘protease
inhibitor’. In all tables, any score stable > 0 is considered an actual
positive and any score stable  0 is considered an actual negative.
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Supplementary descriptions of the benchmark data sets,
Supplementary section on the impact of chosen seed for
random number generation, Supplementary description of
the benchmarks strategy, Supplementary Tables of HIV-1
PIs and abbreviations.
ACKNOWLEDGEMENTS
The authors thank Martin Blythe for coming up with the
name SigniSite.
FUNDING
National Institutes of Health [HHSN272201200010C]; EU
FP7 PepChipOmics: The European Union 7th
Framework Program FP7/2007-2013 [222773]; The
Center for Genomic Epidemiology (www.genomicepide-
miology.org) grant 09-067103/DSF from the Danish
Council for Strategic Research; The University of
Copenhagen - Program of Excellence. Funding for open
access charge: Technical University of Denmark - PhD
programme.
Conﬂict of interest statement. None declared.
REFERENCES
1. Shcherbo,D., Shemiakina,I.I., Ryabova,A.V., Luker,K.E.,
Schmidt,B.T., Souslova,E.A., Gorodnicheva,T.V., Strukova,L.,
Shidlovskiy,K.M., Britanova,O.V. et al. (2010) Near-infrared
ﬂuorescent proteins. Nat. Methods, 7, 827–829.
2. Gnidehou,S., Jessen,L., Gangnard,S., Ermont,C., Triqui,C.,
Quiviger,M., Guitard,J., Lund,O., Deloron,P. and Ndam,N.T.
(2010) Insight into antigenic diversity of VAR2CSA-DBL5E
Domain from multiple Plasmodium falciparum placental isolates.
PLoS One, 5, e13105.
3. Brandt,B.W., Feenstra,K.A. and Heringa,J. (2010) Multi-
Harmony: detecting functional speciﬁcity from sequence
alignment. Nucleic Acids Res., 38, 35–40.
4. Capra,J.A. and Singh,M. (2008) Characterization and prediction
of residues determining protein functional speciﬁcity.
Bioinformatics, 24, 1473–1480.
5. Chakrabarti,S., Bryant,S.H. and Panchenko,A.R. (2007)
Functional speciﬁcity lies within the properties and evolutionary
changes of amino acids. J. Mol. Biol., 373, 801–810.
6. Kalinina,O.V., Novichkov,P.S., Mironov,A.A., Gelfand,M.S. and
Rakhmaninova,A.B. (2004) SDPpred: a tool for prediction of
amino acid residues that determine differences in functional
speciﬁcity of homologous proteins. Nucleic Acids Res., 32,
W424–W428.
7. Pei,J., Cai,W., Kinch,L.N. and Grishin,N.V. (2006) Prediction of
functional speciﬁcity determinants from protein sequences using
log-likelihood ratios. Bioinformatics, 22, 164–171.
8. Ye,K., Feenstra,K.A., Heringa,J., Ijzerman,A.P. and Marchiori,E.
(2008) Multi-RELIEF: a method to recognize speciﬁcity
determining residues from multiple sequence alignments using a
Machine-Learning approach for feature weighting. Bioinformatics,
24, 18–25.
9. Buslje,C.M., Teppa,E., Domnico,T.D., Delﬁno,J.M. and
Nielsen,M. (2010) Networks of high mutual information deﬁne
the structural proximity of catalytic sites: implications for
catalytic residue identiﬁcation. PLoS Comput. Biol., 6, e1000978.
10. Lichtarge,O., Bourne,H.R. and Cohen,F.E. (1996) An
evolutionary trace method deﬁnes binding surfaces common to
protein families. J. Mol. Biol., 257, 342–358.
11. Dudoit,S., Yang,Y.H., Callow,M.J. and Speed,T.P. (2002)
Statistical methods for identifying differentially expressed genes
in replicated cDNA microarray experiments. Stat. Sin., 12,
111–139.
12. Katoh,K., Misawa,K., Kuma,K.I. and Miyata,T. (2002) MAFFT:
a novel method for rapid multiple sequence alignment based on
fast Fourier transform. Nucleic Acids Res., 30, 3059–3066.
13. Thomsen,M.C.F. and Nielsen,M. (2012) Seq2Logo: a method for
construction and visualization of amino acid binding motifs and
sequence proﬁles including sequence weighting, pseudo counts and
two-sided representation of amino acid enrichment and depletion.
Nucleic Acids Res., 40, W281–W287.
14. Lund,O., Nielsen,M., Lundegaard,C., Kesmir,C. and Brunak,S.
(2005) Immunological Bioinformatics. The MIT Press, Cambridge,
MA, London, England.
15. Rhee,S.Y., Gonzales,M.J., Kantor,R., Betts,B.J., Ravela,J. and
Shafer,R.W. (2003) Human immunodeﬁciency virus reverse
transcriptase and protease sequence database. Nucleic Acids Res.,
30, 298–303.
16. Shafer,R.W. (2006) Rationale and uses of a public HIV drug-
resistance database. J. Infect. Dis., 194, S51–S58.
17. Johnson,V.A., Calvez,V., Gnthard,H.F., Paredes,R., Pillay,D.,
Shafer,R., Wensing,A.M. and Richman,D.D. (2013) Update of
the drug resistance mutations in HIV-1: March 2013. Top Antivir.
Med., 21, 6–14.
18. Chakrabarti,S. and Panchenko,A.R. (2009) Ensemble approach to
predict speciﬁcity determinants: benchmarking and validation.
BMC Bioinformatics, 373, 801–810.
19. Chakraborty,A., Mandloi,S., Lanczycki,C.J., Panchenko,A.R. and
Chakrabarti,S. (2012) SPEER-SERVER: a web server for
prediction of protein speciﬁcity determining sites. Nucleic Acids
Res., 40, W242–W248.
20. Healy,D.G., Falchi,M., O’Sullivan,S.S., Bonifati,V., Durr,A.,
Bressman,S., Brice,A., Aasly,J., Zabetian,C.P., Goldwurm,S. et al.
(2008) Phenotype, genotype, and worldwide genetic penetrance of
LRRK2-associated Parkinson’s disease: a case-control study.
Lancet Neurol., 7, 583–590.
21. Dendrou,C.A., Plagnol,V., Fung,E., Yang,J.H., Downes,K.,
Cooper,J.D., Nutland,S., Coleman,G., Himsworth,M., Hardy,M.
et al. (2009) Cell-speciﬁc protein phenotypes for the autoimmune
locus IL2RA using a genotype-selectable human bioresource.
Nat. Genet., 41, 1011–1015.
22. Armitage,P., Berry,G. and Matthews,J.N.S. (2002) Statistical
Methods in Medical Research. Blackwell Publishing Company,
Malden, MA, USA.
Nucleic Acids Research, 2013, Vol. 41, Web Server issue W291
 at D
TU
 Library on July 15, 2013
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
